0 CHECKOUT

Hepatitis D - Pipeline Review, H1 2015

  • ID: 3243310
  • April 2015
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • BioDiem Ltd
  • Biogenomics Limited
  • Globeimmune, Inc.
  • Johnson & Johnson
  • REPLICor Inc.
  • SomaGenics Inc.
  • MORE

Hepatitis D - Pipeline Review, H1 2015

Summary

This, ‘Hepatitis D - Pipeline Review, H1 2015’, provides an overview of the Hepatitis D’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis D, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis D and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BioDiem Ltd
  • Biogenomics Limited
  • Globeimmune, Inc.
  • Johnson & Johnson
  • REPLICor Inc.
  • SomaGenics Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hepatitis D Overview
Therapeutics Development
Pipeline Products for Hepatitis D - Overview
Pipeline Products for Hepatitis D - Comparative Analysis
Hepatitis D - Therapeutics under Development by Companies
Hepatitis D - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Hepatitis D - Products under Development by Companies
Hepatitis D - Companies Involved in Therapeutics Development
Alnylam Pharmaceuticals, Inc.
BioDiem Ltd
Biogenomics Limited
Eiger BioPharmaceuticals, Inc.
Globeimmune, Inc.
Johnson & Johnson
REPLICor Inc.
SomaGenics Inc.
Hepatitis D - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALN-HDV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EBP-921 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GI-18000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hepatitis D vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lonafarnib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myrcludex-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REP-9-AC' - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide for Hepatitis D - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tipifarnib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hepatitis D - Recent Pipeline Updates
Hepatitis D - Product Development Milestones
Featured News & Press Releases
Apr 13, 2015: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Conference - April 22 to 26, 2015
Apr 10, 2015: Replicor to Present at the 2015 Lancet Viral Hepatitis Conference
Apr 02, 2015: Replicor Announces Completion of Enrollment in Phase II Trial
Feb 23, 2015: Eiger BioPharmaceuticals Announces Presentation of Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib
Dec 22, 2014: Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting
Dec 22, 2014: Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for Hepatitis Delta Virus (HDV) Infection
Oct 01, 2014: REPLICor announces initiation of its Phase II clinical trial with REP 2139-Ca in combination with Pegasys in patients with hepatitis B / hepatitis D co-infection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hepatitis D, H1 2015
Number of Products under Development for Hepatitis D - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Hepatitis D - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015
Hepatitis D - Pipeline by BioDiem Ltd, H1 2015
Hepatitis D - Pipeline by Biogenomics Limited, H1 2015
Hepatitis D - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2015
Hepatitis D - Pipeline by Globeimmune, Inc., H1 2015
Hepatitis D - Pipeline by Johnson & Johnson, H1 2015
Hepatitis D - Pipeline by REPLICor Inc., H1 2015
Hepatitis D - Pipeline by SomaGenics Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hepatitis D Therapeutics - Recent Pipeline Updates, H1 2015

List of Figures
Number of Products under Development for Hepatitis D, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Alnylam Pharmaceuticals, Inc.
- BioDiem Ltd
- Biogenomics Limited
- Eiger BioPharmaceuticals, Inc.
- Globeimmune, Inc.
- Johnson & Johnson
- REPLICor Inc.
- SomaGenics Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.